Topics


Glioblastoma | Treatment | Targeted therapy | Ipilimumab






Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Ipilimumab





Ipilumab, Nivolumab

Sloan AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M, Mehta MP.
NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM.
Neuro Oncol. 2024 Jun 14:noae058. doi: 10.1093/neuonc/noae058. PMID: 38874333. Interventional study˰ ˍ



Ipilumab, Nivolumab, Relatlimab

Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U, Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA, Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM, Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H.
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.
Nat Med. 2025 Feb 27. doi: 10.1038/s41591-025-03512-1. PMID: 40016450. Case report. ˍ